The Board of Directors at its Meeting held on May 8, 2026 recommended final dividend of Re. 0.45 per share for FY26
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported strong FY26 results with standalone revenue from operations growing 16.1% to Rs. 1,06,049.17 Lacs (FY25: Rs. 91,326.13 Lacs). Net profit after tax increased 23.9% to Rs. 10,344.15 Lacs (FY25: Rs. 8,345.78 Lacs). The Board recommended a final dividend of Rs. 0.45 per equity share (45% on face value of Re. 1), subject to shareholder approval at the ensuing AGM. Additionally, Mr. Tapan Mitra was appointed as Additional Independent Director and Dr. Girdhar J. Gyani's appointment is sought for approval. M/s. T R Chadha & Co LLP was re-appointed as statutory auditors for a second term of 5 years. Auditors issued unmodified opinion on both standalone and consolidated financial results. An exceptional item of Rs. 307.44 Lacs was recorded due to the impact of new Labour Codes on employee benefits.
The company delivered robust double-digit revenue and profit growth in FY26. The 45% dividend payout signals confidence in financial health, though the absolute amount is modest. Unmodified audit opinions indicate no going concern or material issues.